Orlucent® Inc.

Join us at the American Academy of Dermatology Meeting in Denver where Sancy Leachman MD PhD will present our oral poster, #77303 Clinical Utility of Skin Fluorescent Imaging for Melanoma and High-Grade Dysplasia. Friday, March 27 at 2:10 pm in Lobby C Poster Center 2. #AAD2026

New innovation alert! The Orlucent® Skin Fluorescent Imaging System was featured in @pspmag in an article titled: Study Finds Noninvasive Imaging Improves Accuracy in Evaluating Suspicious Moles. plasticsurgerypractice.com/client-objecti…

Our appreciation to @ONAcom for providing in-depth trial coverage in the article: Skin Fluorescence Imaging Accurately Flags High-Risk Melanocytic Lesions. We are honored that Dermatology Daily also cited the study as headline news on February 13, 2026. oncologynurseadvisor.com/news/melanoma-…

Many thanks to @InvestorHangout and for authoring the post titled: Revolutionary Imaging System Enhances Melanoma Detection Efforts. investorshangout.com/revolutionary-…

In this interview by The Pathologist CEO Dr. Catherine Shachaf discusses the implications of Orlucent pivotal trial results. Read the post titled Fluorescent Imaging Demystifies Melanoma. thepathologist.com/issues/2026/ar…

We are excited to see Applied Radiology’s coverage of our pivotal clinical trial results in the article titled “Orlucent’s Handheld Imaging Device Shows High Accuracy for Non-Invasive Melanoma Detection.” #SkinCancerDetection #Melanoma #PigmentedLesions appliedradiology.com/articles/orluc…

MedTech Outlook recognized Orlucent with a feature article and award for Handheld Fluorescent Molecular Imaging System of the year. Read the article. medicaltechoutlook.com/orlucent-2026 #SkinCancerDetection #Melanoma #PigmentedLesions

The Orlucent team has co-authored a review article in Technology in Cancer Research and Treatment which discusses the uses, advantages and limitations of molecular imaging methods employed in the detection of skin cancers. Read the article journals.sagepub.com/doi/10.1177/15…

We are deeply saddened by the passing of Dr. Thomas J. Fogarty, (1934-2025) on December 28, 2025. Dr. Fogarty played a pivotal role in getting Orlucent started, and we will always be grateful for his belief in our mission.

We are pleased to announce the results of the Orlucent® pivotal study have been published in the February issue of the Journal of American Academy of Dermatology (JAAD) International. Read the press release. #SkinCancerDetection #Melanoma #PigmentedLesions prnewswire.com/news-releases/…

Orlucent Demonstrates Accurate, Non-Invasive Detection in vivo of Melanoma-Related Activity Using First-in-Kind Ha... prn.to/3U2fMNF

Orlucent Receives FDA Breakthrough Device Designation for Handheld Mole Imaging System prnewswire.com/news-releases/…